Treatment of cardiac amyloid light-chain amyloidosis with the green tea compound epigallocatechin-3-galiate
ISRCTN | ISRCTN68399350 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN68399350 |
EudraCT/CTIS number | 2012-004520-38 |
Secondary identifying numbers | N/A |
- Submission date
- 29/09/2012
- Registration date
- 05/10/2012
- Last edited
- 30/11/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Background and study aims
Systemic amyloid light-chain amyloidosis is a rare but serious condition where abnormal bone marrow cells produce excessive amounts of abnormal proteins, which form deposits called amyloid in tissues and organs throughout the body. Amyloid deposited in the heart can cause it to become enlarged and impair its ability to pump blood efficiently around the body, which may result in heart failure. Treatment currently involves having chemotherapy to damage the abnormal bone marrow cells and stop the production of the abnormal proteins. Epigallocatechin-3-gallate (EGCG), a chemical found in found in green tea, may be able to reduce the formation of amyloid and break it down. The aim of this study is to find out whether EGCG is able to reduce amyloid deposition in the heart.
Who can participate?
Patients with systemic amyloid light-chain amyloidosis affecting the heart
What does the study involve?
Participants are randomly allocated to take either increasing doses of EGCG capsules or a placebo (dummy drug) for 12 months. Participants come to the center for tests every 3 months. Echocardiography (a heart scan) is performed every 6 months. A heart MRI scan is carried out at the beginning and at the end of treatment.
What are the possible benefits and risks of participating?
EGCG may help to break down amyloid in the heart. There are no known risks of EGCG treatment.
Where is the study run from?
Ruprecht-Karls-University of Heidelberg (Germany)
When is the study starting and how long is it expected to run for?
December 2012 to November 2017
Who is funding the study?
Federal Ministry of Education and Research (Germany)
Who is the main contact?
Dr Stefan Schönland
stefan.schoenland@med.uni-heidelberg.de
Contact information
Scientific
Medical Department V
(Hematology/Amyloidosis Clinic)
Im Neuenheimer Feld 672
Heidelberg
D-69120
Germany
stefan.schoenland@med.uni-heidelberg.de |
Study information
Study design | Randomised placebo-controlled double-blind single-centre phase IIb study |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
Scientific title | A randomised trial for the Treatment of cardiac AMyloid light-chain amyloidosis with the green tea compound Epigallocatechin-3-gALlate (TAME-AL) |
Study acronym | TAME-AL |
Study objectives | One year treatment with Epigallocatechin-3-gallate (EGCG) reduces cardiac mass in patients with AL amyloidosis. |
Ethics approval(s) | Ethics Committee of The University Heidelberg, 08/04/2013, ref: AFmo-008/2013 |
Health condition(s) or problem(s) studied | Amyloid light-chain amyloidosis |
Intervention | EGCG capsules 400-1200 mg in increasing dosages or placebo for 1 year |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase II |
Drug / device / biological / vaccine name(s) | Epigallocatechin-3-gallate |
Primary outcome measure | Left ventricular mass, measured by cardiac MRI |
Secondary outcome measures | 1. Quality of life, measured using the EORTC-QLQ-C30 2. Left ventricle (LV) end diastolic and end systolic volumes with resulting ejection fraction, measured by cardiac MRI 3. Cardiac function parameters (calculated left ventricular mass, Tissue DI, TAPSE, MAPSE) 4. Cardiac biomarkers (cardiac troponin T hsTNT, NTproBNP) 5. 6-minute walk distance 6. Organ response in other affected organs, Gertz et al., 2005; standard criteria 7. Improvement of hematological remission 8. Overall survival 9. Correlation of epigallocatechin gallate (EGCG) serum levels with organ response 10. Number of adverse events according to Common Toxicity Criteria (CTC) version 4.0 Measured 12 months after the start of treatment |
Overall study start date | 01/12/2012 |
Completion date | 10/11/2017 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 38 |
Key inclusion criteria | 1. Biopsy proven systemic AL amyloidosis 2. Cardiac involvement with septum thickness >12 mm (without other causes as published by Gertz et al) 3. Hypertension or other potential causes of left ventricular hypertrophy 4. Previously treated with chemotherapy 5. Induced at least a very good partial remission of the underlying monoclonal plasma cell or B cell disorder |
Key exclusion criteria | 1. Age < 18 years 2. Concomitant multiple myeloma stage II and III (Salmon and Durie) 3. Concurrent chemotherapy necessary 4. Time to last chemotherapy > 6 months 5. Chronic liver disease 6. Bilirubin > 1,5 mg/dl 7. Not able to visit Amyloidosis Clinic in Heidelberg every 3 months |
Date of first enrolment | 01/12/2012 |
Date of final enrolment | 01/10/2016 |
Locations
Countries of recruitment
- Germany
Study participating centre
D-69120
Germany
Sponsor information
University/education
Medical Faculty, represented by Universitätsklinikum Heidelberg
Im Neuenheimer Feld 672
Heidelberg
D-69120
Germany
irmtraud.guerkan@med.uni-heidelberg.de | |
https://ror.org/038t36y30 |
Funders
Funder type
Government
Government organisation / National government
- Alternative name(s)
- Federal Ministry of Education and Research, BMBF
- Location
- Germany
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | To be confirmed at a later date |
IPD sharing plan |
Editorial Notes
22/11/2016: Plain English summary added.
08/11/2016: The overall trial end date has been updated from 30/11/2015 to 10/11/2017.